Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C

Sharara, A.I., Hunt, C.M., et al., 1996, Hepatitis C. Ann Intern Med 125:658–68.PubMedGoogle Scholar

Koziel, M.J., 1996, Immunology of viral hepatitis. Am J Med 100:98–109.CrossRefPubMedGoogle Scholar

Kiyasu, P.K. and Caldwell, S.H., 1993, Diagnosis and treatment of the major hepatotropic viruses. Am J Med Sci 306: 248–61.PubMedGoogle Scholar

Iwarson, S., Norkraus, G. et al., 1995, Hepatitis C: natural history of a unique infection. Clin Infect Dis 20: 1361–70.PubMedGoogle Scholar

Alter, M., 1997, Epidemiology of hepatitis C. Hepatology 26:(3 Suppl 1): 625–655.Google Scholar

Davis, G.L., 2000, Current therapy for chronic hepatitis C. Gastroenterol 118(Suppl 1): S104–S114.Google Scholar

Lawrence, S.P., 2000, Advances in the treatment of hepatitis C. In Advances in Internal Medicine. Mosby, St. Louis.Google Scholar

Hoofnagle, J.H. and di Bisceglie, A.M., 1997, The treatment of chronic viral hepatitis. N Engl J Med 336: 347–56.CrossRefPubMedGoogle Scholar

McHutchinson, J.G., Gordon, S.C., et. al., 1998, Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485–92.Google Scholar

Wills, R.J., 1990, Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390–399.PubMedGoogle Scholar

Bocci, V., Pacini, A. et. al., 1981, Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 1: 347–52.PubMedGoogle Scholar

Zeuzem, S., Herrmann, E. et. al., 2001, Viral kinetics with chronic hepatitis C patients treated with standard or peginterferon alfa-2a. Gastroenterol 120: 1438–1447.Google Scholar

Lam, N.P. Neumann, A.U. et. al., 1997, Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226–31.PubMedGoogle Scholar

Zhi, J., Teller, S.B. et al., 1995, Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2b given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 35: 281–4.PubMedGoogle Scholar

Harris, J.M., Martin, N.E., et. al., 2001, Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539–51.PubMedGoogle Scholar

Yamaoka, T., Tabata, Y., et. al., 1994, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm Sci 83: 601–6.PubMedGoogle Scholar

Fung, W.-J., Porter, J.E., et. al., 1997, Strategies for the preparation and characterization of polyethylene glycol vinyl sulfone. Polymers Preprint: 565–66.Google Scholar

Nieforth, K.A., Nadeau, R., et. al., 1996, Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 59: 636–46.CrossRefPubMedGoogle Scholar

Xu, Z.-X., Patel, I., et al., 1998, Single-dose safety, tolerability and pharmacokinetics of PEG-FIN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 28(Suppl): 702.Google Scholar

Bailon, P., Palleroni, A., et al., 2001, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12: 195–202.CrossRefGoogle Scholar

Bailon, P., Spence, C., et al., 1999, Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a. Antiviral Therapy 4(Suppl 4): 27.Google Scholar

Harris, N.J., Veronese, F.M., et al., 1999, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces. US Patent & Trademark Office, USA.Google Scholar

Algranati, N.E., Sy, S., et. al., 1999, A branched methoxy 40 kDa, polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of PEG-IFN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 40: 190.Google Scholar

Modi, M.W., Fried, M.W., et. al., 2000, The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis patients after multiple dosing. Hepatology 32 (4 Pt 2 of 2): 394A.Google Scholar

Zeuzem, S., Feinman, S.V., et al., 2000, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666–72.CrossRefPubMedGoogle Scholar

Heathcote, E.J., Shiftman, M.J., et. al., 2000, Peginterferon alfa-2a in patieints with chronic hepatitis C and cirrhosis. N Engl J Med 345: 1673–80.Google Scholar